论文部分内容阅读
[目的]评价单药多西他赛周方案治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和毒副作用。[方法]2000年10月～2006年3月收治的65例年龄63～82岁老年晚期NSCLC患者应用单药多西他赛周方案化疗,剂量为35mg/(m2·w),连用3周,休息1周,治疗有效者最多接受16周治疗或至疾病进展。[结果]65例患者共接受503周多西他赛化疗,PR19例,有效率29.2%;稳定26例,占40%。1年生存率32.4%,2年生存率8.6%。主要毒副作用轻微。[结论]单药多西他赛周方案治疗老年晚期NSCLC耐受性良好,安全有效。
[Objective] To evaluate the clinical efficacy and side effects of single-drug docetaxel-week regimen in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). [Method] Sixty-five elderly patients with advanced NSCLC aged 63 to 82 years who were treated from October 2000 to March 2006 were treated with single-dose docetaxel weekly at a dose of 35 mg / (m2 · w) for 3 weeks, Take a week off, the treatment effective up to 16 weeks of treatment or disease progression. [Results] The total of 65 patients received 503 weeks of docetaxel chemotherapy, PR19 cases, the effective rate of 29.2%; stable in 26 cases, accounting for 40%. The 1-year survival rate was 32.4% and the 2-year survival rate was 8.6%. The main side effects of minor. [Conclusion] The single-drug docetaxel-week regimen is safe, effective and safe for the treatment of elderly patients with advanced NSCLC.